Recent advances in genetic predisposition of myasthenia gravis

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Zagoriti, Zoi ^a   Kambouris, Manousos E ^a   Patrinos, George P ^a   Tzartos, Socrates J ^a,b   Poulas, Konstantinos ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TRANSCRIPTION FACTOR FOXP3; DNA BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PTPN22 PROTEIN, HUMAN; TNIP1 PROTEIN, HUMAN;

ALLELE; CONGENITAL MYASTHENIC SYNDROME; DISEASE SEVERITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; MYASTHENIA GRAVIS; ONSET AGE; REVIEW; THYMOMA; GENETICS; PATHOPHYSIOLOGY;

AGE OF ONSET; ALLELES; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MYASTHENIA GRAVIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22;

EID: 84889009411     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/404053     Document Type: Review

References (68)

1. Gomez A. M., van den Broeck J., Vrolix K., Janssen S. P., Lemmens M. A. M., van der Esch E., Duimel H., Frederik P., Molenaar P. C., Martnez-Martnez P., de Baets M. H., Losen M., Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 2010 43 5-6 353 370 2-s2.0-77955889499 10.3109/08916930903555943
2. Lindstrom J. M., Seybold M. E., Lennon V. A., Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976 26 11 1054 1059 2-s2.0-0017171683
3. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A., Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 2001 7 3 365 368 2-s2.0-0035105784 10.1038/85520 (Pubitemid 32224355)
4. Pevzner A., Schoser B., Peters K., Cosma N.-C., Karakatsani A., Schalke B., Melms A., Kröger S., Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. Journal of Neurology 2011 259 3 427 435 2-s2.0-79960889509 10.1007/s00415-011-6194-7
5. Zhang B., Tzartos J. S., Belimezi M., Ragheb S., Bealmear B., Lewis R. A., Xiong W.-C., Lisak R. P., Tzartos S. J., Mei L., Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Archives of Neurology 2012 69 4 445 451 2-s2.0-84859939384 10.1001/archneurol.2011.2393
6. Tzartos S. J., Kokla A., Walgrave S. L., Conti-Tronconi B. M., Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the α subunit. Proceedings of the National Academy of Sciences of the United States of America 1988 85 9 2899 2908 2-s2.0-0001707341
7. Tzartos S. J., Barkas T., Cung M. T., Mamalaki A., Marraud M., Orlewski P., Papanastasiou D., Sakarellos C., Sakarellos-Daitsiotis M., Tsantili P., Tsikaris V., Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunological Reviews 1998 163 89 120 2-s2.0-17344372846 10.1111/j.1600-065X.1998.tb01190.x (Pubitemid 28327864)
8. Meriggioli M. N., Sanders D. B., Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology 2009 8 5 475 490 2-s2.0-64349115066 10.1016/S1474-4422(09)70063-8
9. Giraud M., Beaurain G., Yamamoto A. M., Eymard B., Tranchant C., Gajdos P., Garchon H.-J., Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001 57 9 1555 1560 2-s2.0-0035856431 (Pubitemid 33055467)
10. Verschuuren J. J. G. M., Palace J., Erik Gilhus N., Clinical aspects of myasthenia explained. Autoimmunity 2010 43 5-6 344 352 2-s2.0-77955871486 10.3109/08916931003602130
11. James J. A., Neas B. R., Moser K. L., Hall T., Bruner G. R., Sestak A. L., Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis & Rheumatism 2001 44 5 1122 1126 (Pubitemid 32433618)
12. Balandraud N., Meynard J. B., Auger I., Sovran H., Mugnier B., Reviron D., Roudier J., Roudier C., Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis & Rheumatism 2003 48 5 1223 1228 2-s2.0-0038667529 10.1002/art.10933 (Pubitemid 36554521)
13. Ascherio A., Munger K. L., Lennette E. T., Spiegelman D., Hernán M. A., Olek M. J., Hankinson S. E., Hunter D. J., Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. Journal of the American Medical Association 2001 286 24 3083 3088 2-s2.0-0035956494 (Pubitemid 34016522)
14. Costenbader K. H., Feskanich D., Stampfer M. J., Karlson E. W., Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis & Rheumatism 2007 56 4 1251 1262 2-s2.0-34247193197 10.1002/art.22510 (Pubitemid 46608650)
15. Karlson E. W., Chang S. C., Cui J., Chibnik L. B., Fraser P. A., de Vivo I., Costenbader K. H., Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 1 54 60 2-s2.0-73449089454 10.1136/ard.2008.102962
16. Bogdanos D. P., Smyk D. S., Rigopoulou E. I., Mytilinaiou M. G., Heneghan M. A., Selmi C., Eric Gershwin M., Twin studies in autoimmune disease: genetics, gender and environment. Journal of Autoimmunity 2012 38 2-3 J156 J169 2-s2.0-84858750418 10.1016/j.jaut.2011.11.003
17. Spielman R. S., McGinnis R. E., Ewens W. J., Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). American Journal of Human Genetics 1993 52 3 506 516 2-s2.0-0027377799 (Pubitemid 23311321)
18. Giraud M., Vandiedonck C., Garchon H. J., Genetic factors in autoimmune myasthenia gravis. Annals of the New York Academy of Sciences 2008 1132 180 192 2-s2.0-45249120631 10.1196/annals.1405.027 (Pubitemid 351841369)
19. 151 Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Annals of Neurology 2012 72 6 927 935 10.1002/ana.23691
20. Lefvert A. K., Zhao Y., Ramanujam R., Yu S., Pirskanen R., Hammarström L., PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. Journal of Neuroimmunology 2008 197 2 110 113 2-s2.0-46649095805 10.1016/j.jneuroim.2008.04.004
21. Vandiedonck C., Capdevielle C., Giraud M., Krumeich S., Jais J.-P., Eymard B., Tranchant C., Gajdos P., Garchon H.-J., Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Annals of Neurology 2006 59 2 404 407 2-s2.0-32044456473 10.1002/ana.20751 (Pubitemid 43202499)
22. Zagoriti Z., Georgitsi M., Giannakopoulou O., Genetics of myasthenia gravis: a case-control association study in the Hellenic population. Clinical and Developmental Immunology 2012 2012 7 484919 10.1155/2012/484919
23. Vandiedonck C., Raffoux C., Eymard B., Tranchant C., Dulmet E., Krumeich S., Gajdos P., Garchon H.-J., Association of HLA-A in autoimmune myasthenia gravis with thymoma. Journal of Neuroimmunology 2009 210 1-2 120 123 2-s2.0-67349175324 10.1016/j.jneuroim.2009.02.004
24. Yang H., Hao J., Peng X., Simard A. R., Zhang M., Xie Y., Wang S., The association of HLA-DQA1*0401 and DQB1*0604 with thymomatous myasthenia gravis in Northern Chinese patients. Journal of the Neurological Sciences 2012 312 1-2 57 61 2-s2.0-84155167271 10.1016/j.jns.2011.08.023
25. Rioux J. D., Goyette P., Vyse T. J., Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America 2009 106 44 18680 18685 10.1073/pnas.0909307106
26. Maniaol A. H., Elsais A., Lorentzen Å., Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS ONE 2012 7 5 e36603
27. Xie Y. C., Qu Y., Sun L., Li H.-F., Zhang H., Shi H.-J., Jiang B., Zhao Y., Qiao S.-S., Wang S.-H., Wang D.-X., Association between HLA-DRB1 and myasthenia gravis in a Northern Han Chinese population. Journal of Clinical Neuroscience 2011 18 11 1524 1527 2-s2.0-80053565416 10.1016/j.jocn.2011.05.002
28. Hajeer A. H., Sawidan F. A., Bohlega S., Saleh S., Sutton P., Shubaili A., Tahan A. A., Al Jumah M., HLA class i and class II polymorphisms in Saudi patients with myasthenia gravis. International Journal of Immunogenetics 2009 36 3 169 172 2-s2.0-65649142187 10.1111/j.1744-313X.2009.00843.x
29. Yousefipour G. A., Salami Z., Farjadian S., Association of HLA-DQA1*0101/2 and DQB1*0502 with myasthenia gravis in Southern Iranian patients. Iranian Journal of Immunology 2009 6 2 99 102 2-s2.0-70349232622
30. Fekih-Mrissa N., Klai S., Zaouali J., Gritli N., Mrissa R., Association of HLA-DR/DQ polymorphism with myasthenia gravis in Tunisian patients. Clinical Neurology and Neurosurgery 2013 115 1 32 36 2-s2.0-84859765708 10.1016/j.clineuro.2012.04.001
31. Niks E. H., Kuks J. B. M., Roep B. O., Haasnoot G. W., Verduijn W., Ballieux B. E. P. B., de Baets M. H., Vincent A., Verschuuren J. J. G. M., Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006 66 11 1772 1774 2-s2.0-33745645882 10.1212/01.wnl.0000218159. 79769.5c (Pubitemid 43964645)
32. Bartoccioni E., Scuderi F., Augugliaro A., Chiatamone Ranieri S., Sauchelli D., Alboino P., Marino M., Evoli A., HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009 72 2 195 197 2-s2.0-60549104778 10.1212/01.wnl.0000339103.08830.86
33. Marx A., Willcox N., Leite M. I., Chuang W.-Y., Schalke B., Nix W., Strbel P., Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010 43 5-6 413 427 2-s2.0-77955877122 10.3109/08916930903555935
34. Hasserjian R. P., Ströbel P., Marx A., Pathology of thymic tumors. Seminars in Thoracic and Cardiovascular Surgery 2005 17 1 2 11 10.1053/j.semtcvs.2004.12.002 (Pubitemid 40521324)
35. Ströbel P., Bauer A., Puppe B., Kraushaar T., Krein A., Toyka K., Gold R., Semik M., Kiefer R., Nix W., Schalke B., Müller-Hermelink H. K., Marx A., Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. Journal of Clinical Oncology 2004 22 8 1501 1509 2-s2.0-2342510977 10.1200/JCO.2004.10.113 (Pubitemid 41103633)
36. Giraud M., Beaurain G., Yamamoto A. M., Eymard B., Tranchant C., Gajdos P., Garchon H.-J., Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001 57 9 1555 1560 2-s2.0-0035856431 (Pubitemid 33055467)
37. Vandiedonck C., Beaurain G., Giraud M., Hue-Beauvais C., Eymard B., Tranchant C., Gajdos P., Dausset J., Garchon H.-J., Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthemia gravis and thymus hyperplasia. Proceedings of the National Academy of Sciences of the United States of America 2004 101 43 15464 15469 2-s2.0-7444238973 10.1073/pnas. 0406756101 (Pubitemid 39441564)
38. Leite M. I., Scröbel P., Jones M., Micklem K., Moritz R., Gold R., Niks E. H., Berrih-Aknin S., Scaravilli F., Canelhas A., Marx A., Newsom-Davis J., Willcox N., Vincent A., Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Annals of Neurology 2005 57 3 444 448 2-s2.0-20044374002 10.1002/ana.20386 (Pubitemid 40343969)
39. Rhee I., Veillette A., Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nature Immunology 2012 13 5 439 447 2-s2.0-84859891065 10.1038/ni.2246
40. Burn G. L., Svensson L., Sanchez-Blanco C., Saini M., Cope A. P., Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Letters 2011 585 23 3689 3698 2-s2.0-81755179431 10.1016/j.febslet.2011.04.032
41. Gregersen P. K., Olsson L. M., Recent advances in the genetics of autoimmune disease. Annual Review of Immunology 2009 27 363 391 2-s2.0-67650709487 10.1146/annurev.immunol.021908.132653
42. Zheng J., Ibrahim S., Petersen F., Yu X., Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue. Genes and Immunity 2012 13 8 641 652 10.1038/gene.2012.46
43. Zhang J., Zahir N., Jiang Q., Miliotis H., Heyraud S., Meng X., Dong B., Xie G., Qiu F., Hao Z., McCulloch C. A., Keystone E. C., Peterson A. C., Siminovitch K. A., The autoimmune diseaseg-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nature Genetics 2011 43 9 902 907 2-s2.0-80052239824 10.1038/ng.904
44. Vang T., Congia M., Macis M. D., Musumeci L., Orrú V., Zavattari P., Nika K., Tautz L., Taskén K., Cucca F., Mustelin T., Bottini N., Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nature Genetics 2005 37 12 1317 1319 2-s2.0-28444469783 10.1038/ng1673 (Pubitemid 41722185)
45. Greve B., Hoffmann P., Illes Z., Rozsa C., Berger K., Weissert R., Melms A., The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. Human Immunology 2009 70 7 540 542 2-s2.0-67449141649 10.1016/j.humimm.2009.04.027
46. Chuang W. Y., Ströbel P., Belharazem D., Rieckmann P., Toyka K. V., Nix W., Schalke B., Gold R., Kiefer R., Klinker E., Opitz A., Inoue M., Kuo T.-T., Müller-Hermelink H. K., Marx A., The PTPN22 gain-of-function 1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes and Immunity 2009 10 8 667 672 2-s2.0-73849107060 10.1038/gene.2009.64
47. Provenzano C., Ricciardi R., Scuderi F., Maiuri M. T., Maestri M., La Carpia F., Sferrazza A., Marino M., Leone L., Lucchi M., Mussi A., Zollino M., Evoli A., Bartoccioni E., PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data. Neuromuscular Disorders 2012 22 2 131 138 2-s2.0-84856348555 10.1016/j.nmd.2011.09.003
48. Gregersen P. K., Lee H. S., Batliwalla F., Begovich A. B., PTPN22: setting thresholds for autoimmunity. Seminars in Immunology 2006 18 4 214 223 2-s2.0-33745174905 10.1016/j.smim.2006.03.009 (Pubitemid 43903284)
49. Magistrelli G., Jeannin P., Herbault N., A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. European Journal of Immunology 1999 29 11 3596 3602 (Pubitemid 29527807)
50. Wang X. B., Kakoulidou M., Qiu Q., Giscombe R., Huang D., Pirskanen R., Lefvert A. K., CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes and Immunity 2002 3 1 46 49 2-s2.0-0036483636 10.1038/sj.gene.6363816 (Pubitemid 38961107)
51. Chuang W. Y., Scröbel P., Gold R., Nix W., Schalke B., Kiefer R., Opitz A., Klinker E., Müller-Hermelink H. K., Marx A., A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Annals of Neurology 2005 58 4 644 648 2-s2.0-25444484922 10.1002/ana.20577 (Pubitemid 41377232)
52. Wang X. B., Pirskanen R., Giscombe R., Lefvert A. K., Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. Journal of Internal Medicine 2008 263 1 61 69 2-s2.0-36949013882 10.1111/j.1365-2796.2007.01879.x (Pubitemid 350243551)
53. Liu F. T., Rabinovich G. A., Galectins: regulators of acute and chronic inflammation. Annals of the New York Academy of Sciences 2010 1183 158 182 2-s2.0-75749101401 10.1111/j.1749-6632.2009.05131.x
54. Liu F. T., Yang R. Y., Hsu D. K., Galectins in acute and chronic inflammation. Annals of the New York Academy of Sciences 2012 1253 1 80 91 2-s2.0-84860228899 10.1111/j.1749-6632.2011.06386.x
55. Pál Z., Antal P., Srivastava S. K., Non-synonymous single nucleotide polymorphisms in genes for immunoregulatory galectins: association of galectin-8 (F19Y) occurrence with autoimmune diseases in a Caucasian population. Biochimica et Biophysica Acta 2012 1820 10 1512 1518 10.1016/j.bbagen.2012.05.015
56. Pál Z., Antal P., Millinghoffer A., A novel galectin-1 and interleukin 2 receptor β haplotype is associated with autoimmune myasthenia gravis. Journal of Neuroimmunology 2010 229 1-2 107 111 10.1016/j.jneuroim. 2010.07.015
57. Molnar M. J., Bencsik P., Establishing a neurological-psychiatric biobank: banking, informatics, ethics. Cellular Immunology 2006 244 2 101 104 2-s2.0-34248373840 10.1016/j.cellimm.2007.02.013 (Pubitemid 46738558)
58. Pál Z., Varga Z., Semsei Á., Interleukin-4 receptor alpha polymorphisms in autoimmune myasthenia gravis in a Caucasian population. Human Immunology 2012 73 2 193 195 10.1016/j.humimm.2011.11.001
59. Moore K. W., de Waal Malefyt R., Coffman R. L., O'Garra A., Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 2001 19 683 765 2-s2.0-0035062021 10.1146/annurev.immunol.19.1.683 (Pubitemid 32368050)
60. Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V., An investigation of polymorphism in the interleukin-10 gene promoter. European Journal of Immunogenetics 1997 24 1 1 8 2-s2.0-0031017238 (Pubitemid 27050850)
61. Alseth E. H., Nakkestad H. L., Aarseth J., Gilhus N. E., Skeie G. O., Interleukin-10 promoter polymorphisms in myasthenia gravis. Journal of Neuroimmunology 2009 210 1-2 63 66 2-s2.0-67349177784 10.1016/j.jneuroim.2009. 02.009
62. Thiruppathi M., Rowin J., Li Jiang Q., Sheng J. R., Prabhakar B. S., Meriggioli M. N., Functional defect in regulatory T cells in myasthenia gravis. Annals of the New York Academy of Sciences 2012 1274 68 76 10.1111/j.1749-6632. 2012.06840.x
63. Zhang J., Chen Y., Jia G., FOXP3 -3279 and IVS9+459 polymorphisms are associated with genetic susceptibility to myasthenia gravis. Neuroscience Letters 2013 534 274 278
64. Yousefipour G. A., Haghshenas M. R., Yahyazadeh S., Erfani N., Stromal cell derived factor-1 genetic variation at locus 801 in patients with myasthenia gravis. Iranian Journal of Immunology 2011 8 2 90 95 2-s2.0-80052861883
65. Sakthivel P., Ramanujam R., Wang X. B., Pirskanen R., Lefvert A. K., Programmed death-1: from gene to protein in autoimmune human myasthenia gravis. Journal of Neuroimmunology 2008 193 1-2 149 155 2-s2.0-37749017025 10.1016/j.jneuroim.2007.09.019
66. Pal Z., Gal A., Remenyi V., Tordai A., Molnar M. J., Oestrogen receptor alpha gene intronic polymorphisms and autoimmune myasthenia gravis in Caucasian women. Neuromuscular Disorders 2009 19 12 822 824 2-s2.0-70449524323 10.1016/j.nmd.2009.09.002
67. Ramanujam R., Zhao Y., Pirskanen R., Hammarström L., Lack of association of the CIITA-168A→G promoter SNP with myasthenia gravis and its role in autoimmunity. BMC Medical Genetics 2010 11 1, article 147 2-s2.0-77957744667 10.1186/1471-2350-11-147
68. Ramanujam R., Pirskanen R., Hammarström L., The CD45 77C/G allele is not associated with myasthenia gravis-a reassessment of the potential role of CD45 in autoimmunity. BMC Research Notes 2010 3, article 292 2-s2.0-78149271167 10.1186/1756-0500-3-292